In-depth, evidence-grounded perspectives on the neurobiology, delivery science, and regulatory strategy behind Xycota's programs. All content is preclinical and investigational.
In a 2026 rat model of Fragile X, repeated low doses of psilocybin improved object-recognition memory through a TrkB-dependent pathway without requiring 5-HT2A activation; Xycota is preparing a 28-day human study in mild PTSD to test whether low-dose psilocybin changes clinical symptoms.
Read articlePublished high-dose psychedelic studies report functional unblinding above 90%, while single-dose research in healthy adults has evaluated low-dose oral psilocybin to characterize perceptual thresholds; whether blinding holds during repeated sub-perceptual XYCO-02 dosing in mild PTSD remains an open question.
Read articleCell-derived exosomes are under investigation as transport vehicles across the blood-brain barrier for frontotemporal dementia, where Xycota has filed an FDA Orphan Drug Designation application for preclinical candidate XYCO-01.
Read article